SCHEMBL25346708

SCHEMBL25346708

C[Si](C)(C)CCOCn1cc(-c2ccccc2O)c2ccc(Cl)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.34
NPC1 O15118 1/20 0.34
CCNB2 O95067 1/20 0.33
PRKCB P05771 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
GSK3B P49841 1/20 0.33
RPS6KA3 P51812 1/20 0.33
CCNA1 P78396 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
PDE10A Q9Y233 1/20 0.33
KMT2A Q03164 1/20 0.32
EGFR P00533 1/20 0.32
IGF1R P08069 1/20 0.32
SRC P12931 1/20 0.32
FLT4 P35916 1/20 0.32
KDR P35968 1/20 0.32
FLT3 P36888 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25346910 0.89 DGAT1 (0.34) DGAT1NPC1PRKCBGSK3BPDE10A
SCHEMBL25346315 0.88 BRD4 (0.36) DGAT1NPC1PDE10AKMT2AEGFR
SCHEMBL25346684 0.87 DGAT1 (0.35) DGAT1NPC1PDE10AEGFRIGF1R
SCHEMBL25347805 0.86 EGFR (0.39) DGAT1PRKCBGSK3BPDE10AKMT2A
SCHEMBL25348390 0.84 DGAT1 (0.39) DGAT1PRKCBGSK3BPDE10AEGFR
SCHEMBL25349054 0.84 PDE10A (0.32) DGAT1NPC1PDE10AEGFRIGF1R
SCHEMBL25349352 0.83 DGAT1 (0.37) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL25347418 0.82 DGAT1 (0.34) DGAT1NPC1PDE10AEGFRIGF1R
SCHEMBL25346421 0.82 AKT1 (0.41) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL29513802 0.82 AKT1 (0.41) DGAT1PDE10AEGFRIGF1RSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2024-02-08 US disclosed
EP-4225741-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES Enliven Therapeutics, Inc. (US) 2023-08-16 EP disclosed
WO-2022076973-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR DGAT1 2534/4885NPC1 3334/4885CCNB2 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.